It is shown that vaccine effectiveness against infection and severe, critical, or fatal COVID-19 remained consistent across matching strategies, despite differences in non-COVID-19 mortality, highlighting the importance of using specific outcomes in vaccine effectiveness studies.
Abstract
Health status influences COVID-19 vaccine uptake, with vaccinated individuals generally being healthier than unvaccinated ones. This difference may impact vaccine effectiveness estimates. This study investigated the magnitude of this healthy vaccinee effect on effectiveness estimates. Three national, matched, retrospective cohort studies were conducted on Qatar’s population from February 5, 2020-May 14, 2024, to estimate effectiveness of primary-series and booster vaccinations and of natural infection against infection and severe, critical, or fatal COVID-19. The studies explored three matching scenarios by coexisting conditions, reflecting varying levels of health-status imbalance between vaccinated and unvaccinated individuals. Each matched cohort included >810,000 individuals in the primary-series analysis, >330,000 in the booster analysis, and >730,000 in the natural-infection analysis. Effectiveness was derived from adjusted hazard ratios estimated using Cox regression models. Here we show that vaccine effectiveness against infection and severe, critical, or fatal COVID-19 remained consistent across matching strategies, despite differences in non-COVID-19 mortality. For example, primary-series effectiveness against severe COVID-19 was 96.3% (95% CI: 94.5–97.5) when matching by exact coexisting conditions, 94.2% (95% CI: 92.5–95.6) when matching by number of coexisting conditions, and 94.0% (95% CI: 92.3–95.3) with no matching by coexisting conditions. Similar results were observed in subgroup analyses by follow-up duration and among clinically vulnerable individuals. Comparable findings applied to natural infection’s effectiveness against reinfection and severe COVID-19. Health status differences between vaccinated and unvaccinated individuals did not introduce measurable bias in real-world vaccine effectiveness estimates. Findings highlight the importance of using specific outcomes in vaccine effectiveness studies.
A pronounced HVE was observed for SARS-CoV-2 vaccination during the pandemic, evidenced by markedly lower mortality from causes not plausibly related to vaccination (cancer, external causes) among vaccinated individuals.
U. Riedmann, H. Brenner, J. Ioannidis et al.· medRxiv· 0 citations
Summary Background Annual vaccination is the primary strategy for preventing adverse clinical outcomes associated with seasonal influenza, but vaccine effectiveness varies by season with the degree of antigenic match and the predominant circulating subtype. The 2025–2026 season has been dominated by a newly emerged, an...
Yan Xie, Taeyoung Choi, Ziyad Al-Aly· EClinicalMedicine· 0 citations
Background In 2025, COVID-19 vaccination programmes in England targeted adults aged [≥]75 years and immunosuppressed individuals, with JN.1-based vaccines offered in spring and KP.2-based vaccines offered in autumn. This study evaluated vaccine effectiveness (VE) against COVID-19 hospitalisation following these campaig...
N. A. Aziz, A. Allen, N. Andrews· medRxiv· 0 citations
While vaccines conferring leaky protection against infection and disease tested in settings with very high ARI could modestly underestimate efficacy, trials could be adequately powered with a fraction of the sample size in such settings.
J. Andrews, S. Hermans, Richard G. White et al.· Vaccine· 0 citations
The COVID-19 vaccine saved millions of lives during the pandemic. Clinical trials at the time of authorization and approval showed remarkable effectiveness. However, the effectiveness of the COVID-19 vaccine has changed now that people are no longer naive to the virus. The benefit of vaccination is incrementally lower...
Randy C. Hatton, Laura E. Happe· Journal of Managed Care & Sp...· 0 citations
Promising multicomponent influenza-COVID-19 vaccine candidates currently being evaluated in clinical trials may represent an important advancement in adult immunization strategy, and a meaningful opportunity to strengthen protection against two of the most consequential respiratory pathogens worldwide.
W. Schaffner, S. Gravenstein, S. Kissler et al.· Vaccine· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.